|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
00460 SIHUAN PHARM
Nominal 
1.450 +0.090 (+6.618%) | 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | -- | -- | 1,901,109 | 1,860,539 | 2,181,189 | 3,291,270 |
| Cost of Sales | -- | -- | (659,399) | (564,895) | (693,608) | (842,754) |
| Gross Profit | -- | -- | 1,241,710 | 1,295,644 | 1,487,581 | 2,448,516 |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | (1,727,119) | (131,297) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | 59,228 | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | -- | -- | (15,226) | (53,621) | (80,875) | (158,581) | |
| Profit / (Loss) before Taxation | -- | -- | (428,288) | (161,260) | (2,122,778) | 486,049 | |
| Taxation | -- | -- | (43,261) | (96,427) | (196,794) | (253,279) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | 36,296 | -- | |
| Non-controlling Interests | -- | -- | 254,887 | 203,670 | 368,358 | 183,739 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 179,696 | -- | (216,662) | (54,017) | (1,914,918) | 416,509 | |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | -- | -- | 99,383 | 121,429 | 64,382 | (44,637) |
| Depreciation & Amortisation | -- | -- | 84,995 | 79,735 | 99,150 | 301,463 |
| Directors' Emoluments | -- | -- | 17,141 | 18,497 | 17,937 | 26,895 |
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | 1.970 | -- | -2.340 | -0.580 | -20.520 | 4.420 |
| DPS (cts) | 1.950 | -- | 1.900 | 0.000 | 6.500 | 10.800 |
| Dividend Payout Ratio (%) | 98.985% | -- | -- | -- | -- | 244.344% |
| Cash flow per share ($) | -- | -- | 0.026 | 0.021 | 0.005 | 0.071 |
| NBV per share ($) | -- | -- | 0.470 | 0.475 | 0.508 | 0.888 |
| Remarks: | Real time quote last updated: 01/04/2026 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 179,696 |
| %Change | -- |
| EPS / (LPS) | RMB 0.020 |
| NBV Per Share (¥) | RMB -- |